178 related articles for article (PubMed ID: 19786840)
1. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
Esteban M
Hum Vaccin; 2009 Dec; 5(12):867-71. PubMed ID: 19786840
[TBL] [Abstract][Full Text] [Related]
2. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
3. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of Modified Vaccinia virus Ankara vaccines.
Gilbert SC
Vaccine; 2013 Sep; 31(39):4241-6. PubMed ID: 23523410
[TBL] [Abstract][Full Text] [Related]
6. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B; Pérez P; Marcos-Villar L; Albericio G; Astorgano D; Álvarez E; Sin L; Gómez CE; García-Arriaza J; Esteban M
J Mol Biol; 2023 Aug; 435(15):168173. PubMed ID: 37301278
[TBL] [Abstract][Full Text] [Related]
7. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
[TBL] [Abstract][Full Text] [Related]
9. Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.
Gómez CE; Perdiguero B; Sánchez-Corzo C; Sorzano COS; Esteban M
Viruses; 2017 Dec; 10(1):. PubMed ID: 29280955
[TBL] [Abstract][Full Text] [Related]
10. MVA and NYVAC as vaccines against emergent infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Perdiguero B; Esteban M
Curr Gene Ther; 2011 Jun; 11(3):189-217. PubMed ID: 21453284
[TBL] [Abstract][Full Text] [Related]
11. Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.
Nájera JL; Gómez CE; García-Arriaza J; Sorzano CO; Esteban M
PLoS One; 2010 Jun; 5(6):e11406. PubMed ID: 20613977
[TBL] [Abstract][Full Text] [Related]
12. Poxvirus vector-based HIV vaccines.
Pantaleo G; Esteban M; Jacobs B; Tartaglia J
Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379
[TBL] [Abstract][Full Text] [Related]
13. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.
Guerra S; Nájera JL; González JM; López-Fernández LA; Climent N; Gatell JM; Gallart T; Esteban M
J Virol; 2007 Aug; 81(16):8707-21. PubMed ID: 17537851
[TBL] [Abstract][Full Text] [Related]
14. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
[TBL] [Abstract][Full Text] [Related]
15. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
17. MVA as a vector for vaccines against HIV-1.
Im EJ; Hanke T
Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S89-97. PubMed ID: 15285708
[TBL] [Abstract][Full Text] [Related]
18. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
20. Recombinant MVA vaccines: dispelling the myths.
Cottingham MG; Carroll MW
Vaccine; 2013 Sep; 31(39):4247-51. PubMed ID: 23523407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]